Speaker Profile
PhD, Co-Founder and Co-CEO, Guardant Health
Biography
Dr. AmirAli Talasaz is a renowned leader and innovator in the field of precision medicine, with a focus on advancing noninvasive liquid biopsy technologies. He has made significant contributions to the development and implementation of cutting edge diagnostic tools that have revolutionized the detection and monitoring of cancer. Dr. Talasaz currently serves as cofounder and coCEO of Guardant Health. Prior to cofounding Guardant Health, he was Senior Director of Diagnostics Research at Illumina and led efforts to develop next generation genomic analysis for emerging clinical applications. Before Illumina, he founded Auriphex Biosciences, which focused on the purification and genetic analysis of circulating tumor cells for cancer management. The technology was acquired by Illumina in 2009. During his academic years, he led the Technology Development group at the Stanford Genome Technology Center. Dr. Talasaz received his Ph.D. in electrical engineering and MSc in management science from Stanford University.
Session Abstract – PMWC 2024 Silicon Valley
Track Chair: Laura J. van 't Veer, UCSF
- PMWC 2024 Award Ceremony
Pioneer Honoree: David Sidransky, Johns Hopkins
Pioneer Honoree: Helmy Eltoukhy
Pioneer Honoree: AmirAli Talasaz, Guardant Health - Utilities of Liquid Biopsy in Biomarker Testing
- Laura Vent Veer, UCSF - Status Quo of Clinical Liquid Biopsy (PANEL)
Chair: Helmy Eltoukhy, Guardant Health
- Sadakatsu Ikeda, Tokyo Medical University
- Heather Parsons, Dana-Farber Cancer Institute
- Sanjay Popat, The Royal Marsden - Liquid Biopsy for Health Monitoring and Disease Prevention (PANEL)
Chair: Anne-Renee Hartman, Adela Bio
- AmirAli Talasaz, Guardant Health
- Heather Parsons, Dana-Farber Cancer Institute
- Mary Pat Lancelotta, Adaptive Bio
- Sylvia Katina Plevritis, Stanford - Multi-Cancer Early Detection Through Multi-Biomarker Class Liquid Biopsy Testing (PANEL)
Chair: Tom Beer, Exact Sciences
- Wendy Rubinstein, National Cancer Institute
- Sheila D. Walcoff, Goldbug Strategies LLC - Keynote: Pioneering Liquid Nucleic Acids Tumor Fragments in Health and Diseases
- David Sidransky, Johns Hopkins - New Approaches in Liquid Biopsy (PANEL)
Chair: Victor Velculescu, Johns Hopkins
- David Sidransky, Johns Hopkins
- Dan Laudau, NY Genome Center
- Daniel De Carvalho, University of Toronto - Global Implications: A scalable Liquid Biopsy for HPV-related Cervical Cancer (PANEL)
Chair: Debra Fraser-Howze, D. Fraser Associates
- Belinda Nedjai, Wolfson Institute of Population Health
- Elisabeth Adams, Aquarius Population Health Limited - NCI Showcase
- Xiaohui Ni, Early Dx
- Daniel Kim, UCSC
